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Abstract 90 
Background. The presence of an early repolarization pattern (ERP) on the surface electrocardiogram 91 
(ECG) is associated with risk of ventricular fibrillation and sudden cardiac death. Family studies have 92 
shown that ERP is a highly heritable trait but molecular genetic determinants are unknown.  93 
Methods. To identify genetic susceptibility loci for ERP, we performed a GWAS and meta-analysis in 94 
2,181 cases and 23,641 controls of European ancestry.  95 
Results. We identified a genome-wide significant (p<5E-8) locus in the KCND3 (potassium voltage 96 
gated channel subfamily D member 3) gene that was successfully replicated in additional 1,124 cases 97 
and 12,510 controls. A subsequent joint meta-analysis of the discovery and replication cohorts 98 
identified rs1545300 as the lead SNP at the KCND3 locus (OR 0.82 per minor T allele, p=7.7E-12), 99 
but did not reveal additional loci. Co-localization analyses indicate causal effects of KCND3 gene 100 
expression levels on ERP in both cardiac left ventricle and tibial artery. 101 
Conclusions. In this study we identified for the first time a genome-wide significant association of a 102 
genetic variant with ERP. Our findings of a locus in the KCND3 gene not only provide insights into the 103 
genetic determinants but also into the pathophysiological mechanism of ERP, discovering a promising 104 
candidate for functional studies. 105 
Funding. For detailed information per study, see Acknowledgments. 106 
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Introduction 107 
The early repolarization pattern (ERP) is a common ECG finding characterized by an elevation at the 108 
QRS-ST junction (J-point) of at least 0.1 mV in two adjacent ECG leads. The prevalence of ERP in the 109 
general population ranges from 2 to 13% being more common in young athletic men(1–5). The 110 
classical notion of ERP being a benign ECG phenotype was challenged in 2008 by the landmark study 111 
of Haissaguerre and colleagues showing an association of ERP with increased risk of ventricular 112 
fibrillation and sudden cardiac death(6): the Early Repolarization Syndrome (ERS)(7). Since then 113 
several studies demonstrated an elevated risk of cardiovascular and all-cause mortality in individuals 114 
with ERP underscoring its arrhythmogenic potential(2, 8, 9). Although the mechanistic basis for 115 
malignant arrhythmias in ERS is unclear, it has been suggested that they occur as a result of an 116 
augmented transmural electrical dispersion of repolarization(10). Ex vivo studies point towards a 117 
central role of the cardiac transient outward potassium current (Ito) in the development of both, ERP 118 
and ERS(11). Furthermore, candidate genetic association studies have highlighted a role for several 119 
genes encoding cardiac ion channels in the development of ERP and ERS(12–15). These genes 120 
include gain-of-function variants in IK-ATP channels (KCNJ8, ABCC9) and loss-of-function variants in 121 
cardiac L-type calcium channels (CACNA1C, CACNB2b, CACNA2D1) and sodium channels (SCN5A, 122 
SCN10A)(16). Interestingly, co-existence of two genetic variants in different ion channel genes with 123 
opposing effects can be observed leading to phenotypic incomplete penetrance of ERP(15). However, 124 
data from functional studies confirming causality are scarce(17). 125 
Studies among relatives of sudden arrhythmic death syndrome show that ERP is more prevalent in the 126 
relatives than in controls indicating that ERP is an important potentially inheritable pro-arrhythmic 127 
trait(18, 19). Moreover, in family studies the heritability estimate for the presence of ERP was h
2
=0.49 128 
(20). However, estimates for common SNP heritability from unrelated individuals are lower(21). This 129 
may explain why the only GWAS on ERP to date failed to identify genetic variants reaching genome-130 
wide significance(22), and indicates the need for larger GWAS with more power. 131 
In order to identify genetic variations that convey susceptibility to ERP we performed a GWAS and 132 
meta-analysis in European ancestry individuals, comprising 2,181 ERP cases and 23,641 controls 133 
from eight cohorts that formed the discovery stage. The findings were taken forward to a replication 134 
stage in 1,124 cases and 12,510 controls from four additional cohorts. To maximize statistical power 135 
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for locus discovery, we subsequently performed a combined discovery and replication cohort GWAS 136 
meta-analysis of 3,305 ERP cases and 36,151 controls. 137 
Results 138 
Clinical characteristics of the study cohorts are depicted in Table 1. The proportion of ERP based on 139 
the definition by Haisaguerre and Macfarlane(6, 23) ranged from 6% to 14% which is in line with 140 
previously reported prevalence in the general population(2–4). 141 
Novel variants associated with ERP  142 
In the first stage, we performed a GWAS meta-analysis in up to 2,181 cases and 23,641 controls from 143 
eight discovery cohorts. In total, 6,976,246 SNPs passed quality control (see Methods). We identified 144 
19 variants spanning 49 kb in KCND3 (Potassium Voltage-Gated Channel Subfamily D Member 3) as 145 
well as rs139772527 (effect allele frequency [EAF] 1.4%, OR=2.57, p=2.0E-8) near HBZ (Hemoglobin 146 
Subunit Zeta) to be genome-wide significantly associated (p<5E-8) with ERP. The SNP with the lowest 147 
p-value in the region (the lead SNP) at KCND3 was the intronic rs12090194 (EAF 32.5%, OR=0.80, 148 
p=4.6E-10), and was replicated in an independent sample of 1,124 cases and 12,510 controls from 149 
four additional cohorts (preplication=2.5E-3, pcombined=9.3E-12, Table 2). The SNP rs139772527 near HBZ 150 
did not fulfil the criteria for replication (preplication=0.28, pcombined=1.4E-6, Table 2) as described in the 151 
Methods. The subsequent combined meta-analysis of all 12 cohorts including up to 39,456 individuals 152 
revealed only the locus at KCND3 to be genome-wide significantly associated with ERP 153 
(Supplementary Figure 1). The lead SNP of the combined GWAS meta-analysis was rs1545300 154 
(EAF 31.9%, OR=0.82, p=7.7E-12), followed by the discovery stage lead SNP rs12090194 being in 155 
strong linkage disequilibrium with rs1545300 (r²=0.96, D’=1) (Figure 1). Both SNPs were imputed at 156 
very high confidence (imputation quality score >0.97) in all cohorts. The quantile-quantile plots did not 157 
show any inflation (individual study λGC between 0.81 and 1.03, median: 0.91), and overall meta-158 
analysis λGC=1.02 (linkage disequilibrium [LD] score regression intercept: 1.01, see Methods) 159 
(Supplementary Figure 2). The result of the combined GWAS meta-analysis was used for the 160 
subsequent analyses. Summary statistics based conditional analysis to select independent hits did not 161 
reveal any secondary signals. The association results for each stage of the lead SNPs with p<1E-6 in 162 
the discovery meta-analysis are provided in Supplementary Table 1. 163 
Statistical finemapping of the associated locus 164 
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All significantly associated SNPs of the combined GWAS meta-analysis were located within KCND3, 165 
the potassium voltage-gated channel subfamily D member 3 gene, and were intronic (Table 3, Figure 166 
2). We used these results to assess whether a single SNP or set of variants drive the association 167 
signal in KCND3 (credible set). The 99% credible set was computed based on Approximate Bayes 168 
Factors for each SNP, resulting for each in a set of SNPs that with 99% posterior probability contained 169 
the variant(s) driving the association signal. For the associated locus at KCND3 the credible set 170 
spanned 49 kb, and contained 19 variants. The two lead SNPs rs1545300 and rs12090194 had a 171 
posterior probability of 21% and 19%, respectively, whereas the former candidate SNP 172 
rs17029069(22) had a posterior probability of 2% (Supplementary Table 2). 173 
To test whether the association in KCND3 might be driven by heart rate or RR interval, we performed 174 
a sensitivity analysis in the 1,253 ERP cases and 11,463 controls of the Lifelines cohort adjusting the 175 
genetic association of rs1545300 additionally for these two traits in separate models. The effect 176 
estimates were virtually unchanged (OR=0.78) with p=1.2E-7 for both adjustments. In addition, we 177 
assessed whether the association of rs1545300 might be related to a specific ERP subtype i.e. ST 178 
segment or ERP localization. In all subtype-stratified analyses the 95% confidence intervals of the 179 
effect sizes overlapped with the overall results not pointing to a subtype driven signal (Supplementary 180 
Table 3).  181 
Expression quantitative trait locus (eQTL) and co-localization 182 
We searched the Genotype-Tissue Expression (GTEx) project database(24) to look for tissue-specific 183 
eQTLs including all genes in vicinity of ±1Mb of the lead SNP rs1545300 and found an association 184 
with KCND3 expression levels in tibial artery (p=3.0E-6, n=388). Two additional eQTL associations of 185 
rs1545300 at FDR<0.2 across the 48 tissues tested were found with KCND3 (ENSG00000171385.5) 186 
in the left ventricle (p=2.9E-4, n=272) of the human heart, and with CEPT1 (ENSG00000134255.9) in 187 
the minor salivary gland (p=3.4E-4, n=85) (Supplementary Table 4). 188 
Subsequent co-localization analyses of rs1545300 in these three tissues revealed also a significant 189 
correlation of gene expression pattern with ERP (pSMR≤0.01) (Figure 3, Supplementary Table 5), 190 
where for the left ventricle the correlation seems to be attributable to the same underlying causative 191 
variant (pHEIDI≥0.05), and for tibial artery the test was close to nominal significance (pHEIDI=0.05). 192 
However, the significant pHEIDI=1.7E-3 of CEPT1 in the minor salivary gland points rather towards a 193 
pleiotropic effect of rs1545300 than to a causal effect of gene expression on ERP in this tissue. For all 194 
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three tissues, an increased gene expression level was associated with a higher risk of ERP 195 
(Supplementary Table 5). 196 
Pleiotropic effects of the lead SNPs 197 
To assess pleiotropic effects of the KCND3 lead SNP rs1545300 or its proxies (r²>0.8), we looked for 198 
genome-wide significant associations in the NHGRI-EBI Catalog of published genome-wide 199 
association studies(25) (accessed: 07/30/2019). Pleiotropic associations were found for P-wave 200 
terminal force (rs12090194 and rs4839185)(26) and for reduced risk of atrial fibrillation per minor allele 201 
(rs1545300 and rs1443926)(27, 28). All these SNPs were in strong linkage disequilibrium (r²>0.97) 202 
with the lead SNP. In addition, variants in low to moderate LD with rs1545300 were associated with P-203 
wave duration (rs2798334, r²=0.26)(29) and ST-T-wave amplitudes (rs12145374, r²=0.60)(30). A 204 
phenome-wide lookup of rs1545300 in the association results of 778 traits available via the Gene 205 
ATLAS web portal (31) using 452,264 individuals of the UK Biobank cohort revealed an association of 206 
the ERP risk reducing minor T allele with reduced risk of heart arrhythmia (estimated OR=0.92, 207 
p=3.6E-6). Of note, no other of the assessed traits reached significance after Bonferroni correction 208 
(p<0.05/778=6.4E-5). 209 
Discussion 210 
In this GWAS meta-analysis comprising 3,305 cases and 36,151 controls including independent 211 
replication samples, we describe an association of ERP with a locus on chromosome 1 in the KCND3 212 
gene. This is the first study identifying a robust genome-wide significant association between genetic 213 
variants and ERP. Our findings provide a candidate gene for further functional studies examining the 214 
pathophysiological mechanism of ERP and potentially ERS. The KCND3 gene encodes the main 215 
pore-forming alpha subunit of the voltage-gated rapidly inactivating A-type potassium channel. In the 216 
cardiac ventricle KCND3 contributes to the fast cardiac transient outward potassium current (Ito), which 217 
plays a major role in the early repolarization phase 1 of the cardiac action potential (AP). 218 
To date, two competing theories explain the presence of J waves and ERP: the repolarization and the 219 
depolarization theory, both involving the Ito channel. On the basis of animal models evidence for the 220 
former is more compelling. Thus, J waves result from a transmural voltage gradient created by a more 221 
prominent epicardial phase 1 AP notch relative to the endocardial AP notch(11, 32). The Ito current 222 
notably influences the degree of the transmural heterogeneity of the phase 1 AP notch and 223 
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consecutively the magnitude of the J wave(11, 32). Pharmacological inhibition of the Ito current with 4-224 
aminopyridine results in a reduction of the J wave amplitude(11). The depolarization theory is based 225 
on clinical overlap of ERP with Brugada syndrome, which has led to the suggestion of Brugada 226 
syndrome being a right ventricular variant of the ERP(33). In theory, deviation from the sequential 227 
activation of cardiac currents INa, Ito, and ICaL can lead to regional conduction slowing and appearance 228 
of inferior and/or lateral ERP(32, 34). In patients with ERS, distinct phenotypes of both delayed 229 
depolarization and early repolarization have been identified(35).  230 
ERP is a highly heritable trait within families(3, 20), however limited heritability can be attributed to 231 
common SNPs in unrelated individuals(21). This might be a reason why the only GWAS to date which 232 
included 452 cases failed to replicate any genome-wide significant loci(22). In our study, which 233 
includes 3,334 cases, we discovered and replicated variants in the KCND3 gene. Interestingly, one of 234 
these variants (rs17029069), which is in moderate LD (r²=0.18, D’=-1) with our lead SNP rs1545300 235 
(Supplementary Figure 3) was reported as a candidate in the earlier GWAS meta-analysis(22). 236 
However, this variant did not replicate in their study, which the authors attributed to limited power 237 
based on the small sample size and/or heterogeneous phenotyping. In our study, experienced 238 
cardiologists evaluated more than 39,000 ECGs with high reproducibility ensuring a very high 239 
phenotyping quality(21). The resulting homogenously assessed phenotype and the substantially 240 
increased number of cases are two aspects that elevated the statistical power of our GWAS meta-241 
analysis. All detected variants cluster in intronic regions of the KCND3 gene, without significant allelic 242 
heterogeneity. The annotation of the locus does not point to a direct pathogenic effect, i.e. a protein 243 
altering mutation, and also the statistical finemapping revealed no single SNP with a substantial 244 
posterior probability (e.g. >80%) of being causal. However, the latter approach has limitations of 245 
detecting rare causal variants due to imputation uncertainty and minimum minor allele frequency 246 
(MAF). Nevertheless, eQTL analysis suggested that the detected variants may affect gene expression 247 
of KCND3. Potential mechanisms include modification of gene expression via altered binding of 248 
transcription factors at cis-elements through enhancers or in DNaseI hypersensitivity regions (Figure 249 
2). This is supported by the results of the test for co-localization showing an increase of ERP risk due 250 
to increased gene expression levels of KCND3 in tissues of the human heart and tibial artery. Similar, 251 
pharmacological ex vivo data predict gain of function mutations in the Ito current to increase the overall 252 
transmural outward shift, leading to an increased epicardial AP notch and thereby inducing ERP in the 253 
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surface ECG(32). Additionally, in close proximity to the lead SNP rs1545300 a long non-coding RNA 254 
(lncRNA), KCND3 antisense RNA 1 (KCND3-AS1) is described. LncRNAs have been shown to 255 
physiologically influence gene regulation through various mechanism e.g. chromatin remodeling, 256 
control of transcription initiation and post-transcriptional processing(36, 37). On the other hand, 257 
dysregulation of lncRNA control circuits can potentially impact development of disease(38): a very 258 
prominent example in cardiovascular diseases is the lncRNA ANRIL, which is a key effector of 9p21 in 259 
atherosclerotic risk and cardiovascular events(38–40). 260 
Given the high prevalence of ERP in the general population and a high MAF of the identified genetic 261 
variants in our study the key question remains why only a very small subset of individuals develops 262 
severe ventricular arrhythmias and ERS. The fine interplay of a genetic predisposition and specific 263 
precipitating conditions might lead to an electrically vulnerable cardiac state. Insights into the potential 264 
origin of ventricular arrhythmias in ERS come from animal models and highlight the role of different ion 265 
channels including Ito(10). A pharmacological model of ERS in canine wedges from the inferior and 266 
lateral ventricular wall showed marked regional dispersion of repolarization (loss of phase 2 AP dome 267 
and AP shortening in some epicardial regions but not others). Presence of transmural repolarization 268 
heterogeneity allowed local re-excitation in form of closely coupled extrasystolic activity (phase 2 re-269 
entry). The combination of an arrhythmogenic substrate, represented by regional electrical instability, 270 
and triggering premature ventricular beats resulted in ventricular fibrillation(10). Human data in ERS 271 
patients suggest that in a subgroup, the ERP is due to a pure repolarization phenotype and 272 
arrhythmia(35) is triggered by Purkinje fiber ectopic beats.  273 
Genetic variants in various ion channel genes have been associated with ERS(16) including the 274 
KCNJ8 and ABCC9 genes encoding the Kir6.1 and ATP-sensing subunits of the KATP channel(6, 12, 275 
41, 42). The commonly implicated variant KCNJ8-p.S422L has a population frequency not consistent 276 
with ERS, and is predicted to be benign by multiple in silico algorithms according to the ClinVar 277 
database(43). A recent study by Chauveau et al. has, however, identified a de novo duplication of the 278 
KCND3 gene in a patient who survived sudden cardiac death and in his 2-year-old daughter(13). Both 279 
exhibited marked ERP in the inferolateral leads that was augmented by bradycardia and pauses in 280 
heart rhythm, in keeping with a repolarization mechanism underlying the ERS phenotype. Studies 281 
have suggested that the inferior region of the left ventricle has a higher density of KCND3 expression 282 
and higher intrinsic levels of Ito(10). This may explain the higher vulnerability of this region for the 283 
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development of ERS in the setting of a genetically mediated gain-of-function in the Ito current. 284 
Moreover, observational studies also identified different ERP subtypes including the occurrence of 285 
ERP in the inferior region and a horizontal/descending ST segment morphology to be associated with 286 
a higher risk of sudden arrhythmic death and cardiovascular mortality(2, 44, 45). However, in a 287 
subgroup of our study the association signal of ERP risk and KCND3 variation was not dominated by a 288 
specific ERP high-risk subtype. Of note the formation of subgroups led to reduction in sample size and 289 
thus statistical power.  290 
Taken together, the rare occurrence of ERS may be explained by different conditions. On the one 291 
hand, an underlying monogenic mutation may be found in some cases. On the other, no single causal 292 
mutation can be identified in the majority of ERS cases rendering the influence of multiple genes and 293 
environmental factors more likely i.e. a 'multi-hit condition'. Similar to other polygenic diseases, the 294 
sum of multiple minor effects of several common genetic variations together with specific external 295 
triggers may affect the occurrence of ERS. There is indeed evidence to suggest that common variants 296 
in the KCND3 locus increase arrhythmogenicity. A phenome-wide lookup of our common lead SNP in 297 
more than 450,000 individuals from the UK Biobank linked the minor T allele associated with reduced 298 
ERP to a reduced risk of heart arrhythmia(31). Furthermore, additional data show an association of 299 
the same common variant with reduced risk of atrial fibrillation(27, 28). A small effect of a common 300 
SNP at KCND3 does not necessarily mean that the variant is benign; rather a single risk allele is 301 
associated with a small but effective change in the gene expression level. Thus, the overall effects of 302 
the KCND3 gene expression levels on the phenotype may appear much stronger compared to the 303 
small effect of rs1545300. Based on our results, it could be hypothesized that variation in KCND3 304 
gene expression levels and subsequently its encoded protein may affect the risk of ERP and 305 
eventually ERS. The positive effect direction of the change in KCND3 gene expression levels in heart 306 
tissue on the risk of ERP estimated via the SMR test (Supplementary Table 5) suggests an elevated 307 
risk with increasing abundance of the KCND3 encoded protein. Functional validation is necessary to 308 
validate this hypothesis and analyses of the KCND3 gene in individuals with ERS is warranted to 309 
confirm the role of KCND3 variation in arrhythmogenesis.  310 
Our study has some limitations, which need to be acknowledged. Presence of ERP in the ECG can be 311 
variable, as it has been described to be dependent on age, heart rate, vagal activity and medication, 312 
although our findings were valid after adjusting for some of these factors. Therefore, we cannot 313 
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exclude that we have missed some individuals with ERP. Second, the tissue-specific gene expression 314 
data used for the co-localization analysis is based on a limited sample size. A larger gene expression 315 
sample or functional studies are needed to validate the revealed effect of KCND3 expression on the 316 
ERP. Also, we analyzed only common and low-frequency SNPs with a MAF >1% missing rare variants 317 
and variants not included in the imputation panel. Finally, long-term outcome data identifying those 318 
individuals with ERP who suffer from ERS are not available. Further GWAS in large international 319 
collaborative cohorts of ERS patients are therefore necessary to determine the genetic risk. 320 
In conclusion, we show for the first time, a robust association of genetic variants with the ERP in a 321 
large GWAS of individuals of European ancestry. The locus in the KCND3 ion channel gene is an 322 
intuitive candidate and supports the theory that at least a proportion of ERS is a pure channelopathy. 323 
Intensive future research will be needed to extend the discovery of ERP susceptibility loci to 324 
individuals of non-European ancestry, and to improve identification and risk stratification of the subset 325 
of individuals with the ERP who are at highest risk for potentially lethal ventricular arrhythmias. 326 
Methods 327 
Study cohorts and SNP genotyping 328 
The discovery stage included 25,822 subjects (2,181 ERP cases) from eight independent cohorts with 329 
genetic and phenotypic data available for analyses: the British Genetics of Hypertension (BRIGHT) 330 
study, the Gutenberg Health Study (GHS1, GHS2), the Genetic Regulation of Arterial Pressure In 331 
humans in the Community (GRAPHIC) study, the Lifelines Cohort Study (Lifelines), the Study of 332 
Health in Pomerania (SHIP, SHIP-Trend), and TwinsUK. Additional 13,634 subjects (1,124 ERP 333 
cases) from four cohorts (Rotterdam Study I, II, III, and CHRIS) were used as independent replication: 334 
the Rotterdam Study (Rotterdam Study I, II, III), and the Cooperative Health Research In South Tyrol 335 
(CHRIS) study. The included subjects of all cohorts were of European ancestry, and all cohorts but 336 
BRIGHT (which sampled hypertensive cases) were population based (Supplementary Table 6). The 337 
determination of the discovery and replication cohorts was determined upfront based on the timeline of 338 
the availability of the genetic and ERP data.  339 
Electrocardiogram analysis and ERP evaluation 340 
12-lead ECGs of all 12 studies were obtained during a study visit in a supine position after 341 
approximately five minutes of rest and were analyzed manually by experienced and specifically trained 342 
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cardiologists for the presence of ERP. In detail, ECGs from TwinsUK and BRIGHT were evaluated in 343 
the UK (YJ, RB, ERB), ECGs from all other cohorts were evaluated in Germany (TT, BK, CH, WR). 344 
Paper-printed 12-lead ECGs were independently read by two experienced clinicians who were blinded 345 
with respect to age and sex. There was very high level of agreement between each pair of interpreters 346 
(95-98%)(20, 21). Cases of ambiguous or unequal phenotype were jointly reassessed by two readers, 347 
and a consensus decision was achieved. To determine interobserver variability between UK and 348 
German teams, a subset of ECGs was analyzed by both teams yielding a concordance of 96%(20, 349 
21). 350 
The ERP phenotype was established according to the definition by Haissaguerre and Macfarlane(6, 351 
23). ERP was defined as elevation of the J-point above the level of QRS onset of ≥0.1 mV in at least 352 
two corresponding leads. To avoid confusion or overlap with Brugada syndrome or arrhythmogenic 353 
right ventricular dysplasia, leads V1 to V3 were excluded from ERP scoring. In case of presence of 354 
ERP, region, either inferior (leads II, III, aVF), antero-lateral (leads I, aVL, V4-V6), or both, and the 355 
maximum amplitude of J-point elevation was documented. Further, the morphology of ERP was 356 
assessed as either notching, slurring or both as well as the ST segment according to Tikkanen and 357 
collegues(44) as either concave/rapidly ascending (>0.1 mV elevation 100 ms after J-point peak or 358 
persistently elevated ST segment >0.1 mV) or horizontal/descending (≤0.1 mV elevation within 100 ms 359 
after J-point peak)(23, 44). In case of a QRS duration of >120 ms or rhythm other than sinus rhythm 360 
(e.g. atrial fibrillation, pacemaker stimulation) ECGs were excluded from the analysis.  361 
Statistics 362 
Unless stated otherwise, the analyses were conducted and plotted using the R statistical software(46), 363 
a Z-test was applied, and all reported p-values are two-sided. 364 
GWAS in individual studies 365 
The GWAS in each study for both the discovery and replication stage was performed on autosomal 366 
imputed SNP genotypes using study-specific quality control protocols which are provided in detail in 367 
Supplementary Table 6. Association analyses were performed using logistic regression for ERP 368 
status as outcome and an additive genetic model on SNP dosages, thus taking genotype uncertainties 369 
of imputed SNPs into account. The analyses were adjusted for age, sex, and relevant study-specific 370 
covariates such as principal components for population stratification (Supplementary Table 6). 371 
Meta-analysis of individual study GWAS results 372 
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The result files from individual studies GWAS underwent extensive quality control before meta-373 
analysis using the gwasqc() function of the GWAtoolbox package v2.2.4(47). The quality control 374 
included file format checks as well as plausibility and distributions of association results including 375 
effect sizes, standard errors, allele frequencies and imputation quality of the SNPs. 376 
The meta-analyses were conducted using a fixed-effect inverse variance weighting as implemented in 377 
Metal(48). Monomorphic SNPs, SNPs with implausible association results (i.e. p≤0, SE≤0, 378 
|log(OR)|≥1000), and SNPs with an imputation quality score ≤0.4 were excluded prior to the meta-379 
analyses resulting in a median of 12,839,202 SNPs per cohort (IQR: 10,756,073-13,184,807). During 380 
the meta-analysis, the study-specific results were corrected by their specific λGC if >1. Results were 381 
checked for possible errors like use of incorrect association model by plotting the association p-values 382 
of the analyses against those from a z-score based meta-analysis for verifying overall concordance. 383 
SNPs that were present in <75% of the total sample size contributing to the respective meta-analysis 384 
or with a MAF ≤0.01 were excluded from subsequent analyses. Finally, data for up to 6,976,246 SNPs 385 
were available after the meta-analysis. 386 
Quantile-quantile plots of the meta-analysis results are provided in Supplementary Figure 2. To 387 
assess whether there was an inflation of p-values in the meta-analysis results attributed to reasons 388 
other than polygenicity, we performed LD score regression(49). The LD score corrected λGC value of 389 
the discovery and replication combined meta-analysis was 1.01, supporting the absence of 390 
unaccounted population stratification. Genome-wide significance was defined as a p-value <5E-8, 391 
corresponding to a Bonferroni correction of one million independent tests(50). The I
2
 statistic was used 392 
to evaluate between-study heterogeneity(51). 393 
To evaluate the presence of allelic heterogeneity within each locus, the GCTA stepwise model 394 
selection procedure (cojo-slct algorithm) was used to identify independent variants employing a step-395 
wise forward selection approach(52). We used the genotype information of 4,081 SHIP individuals for 396 
LD estimation, and set the significance threshold for independent SNPs to 5E-8.  397 
All loci were named according to the nearest gene of the lead SNP. Genomic positions correspond to 398 
build 37 (GRCh37). 399 
Replication analysis 400 
To minimize the burden for multiple testing correction and thus maximizing the power for replication, 401 
the lead SNPs of genome-wide significant loci in the discovery stage were taken forward to the 402 
replication stage in independent samples (Table 1). SNPs were considered as replicated if the p-value 403 
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of a one-sided association test was <0.025 which corresponds to a Bonferroni correction for the two 404 
lead SNPs tested at 5% significance level. 405 
Finally, the GWAS results from the discovery and replication studies were meta-analyzed to search for 406 
additional genome-wide significant loci by maximizing the statistical power for locus discovery. 407 
Gene expression based analyses 408 
The lead SNP rs1545300 of the KCND3 locus of the combined discovery and replication GWAS meta-409 
analysis was tested for cis eQTLs (±1Mb window around the transcription start site) in 48 tissues 410 
available in the GTEx v7 database that included at least 70 samples. Significant associations were 411 
selected based on a Bonferroni corrected p-value <3.0E-5 for the number of genes and tissues tested. 412 
Subsequently, the SNP rs1545300 was tested and plotted for co-localization in the three tissues with 413 
an eQTL FDR<0.2 by applying the SMR method(53) using the GWAS and GTEx eQTL summary 414 
statistics. The method includes a test whether the effect on expression observed at a SNP or at its 415 
proxies is independent of the signal observed in the GWAS, i.e. that gene expression and y are 416 
associated only because of a latent non-genetic confounding variable (SMR test), and a second test 417 
that evaluates if the eQTL and GWAS associations can be attributable to the same causative variant 418 
(HEIDI test). Significance for co-localization of the gene expression and the GWAS signals was 419 
defined by pSMR<0.01, where additionally a pHEIDI≥0.05 indicates the same underlying causal 420 
variant(53). 421 
Data availability 422 
Summary association results of the combined GWAS meta-analysis have been submitted for full 423 
download to the CHARGE dbGaP website under accession phs000930 424 
[https://www.ncbi.nlm.nih.gov/gap]. 425 
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Figure Legends 564 
Figure 1. GWAS results of the KCND3 locus 565 
The results of the combined early repolarization pattern (ERP) GWAS results for the KCND3 locus are 566 
shown for the replicated discovery stage lead SNP rs12090194 in n=38,811 individuals (A and B), and 567 
for the combined GWAS lead SNP rs1545300 in n=38,806 individuals (C and D). The regional 568 
association plots (A and C) show the association results in a ±500 kb region around the lead SNP. 569 
SNPs are plotted on the x-axis according to their chromosomal position with the -log10(p-value) of the 570 
GWAS association on the y-axis. Correlation with the lead SNP (purple) is estimated based on the 571 
1000 Genomes reference samples. Plots were generated using the website of LocusZoom(54). 572 
Genetic positions refer to GRCh37/hg19 coordinates. Forest plots of the respective lead SNPs are 573 
provided in (B) and (D), with odds ratios and their 95% confidence intervals plotted on the x-axis. I² is 574 
the percentage of total variation across studies that is due to heterogeneity. 575 
Figure 2. Location of the significantly associated SNPs within the KCND3 gene 576 
The top 43 SNPs with a genome-wide significance visualized by UCSC Genome Browser(55). All 577 
SNPs mapped into KCND3 gene. The two leads SNPs rs1545300 and rs12090194 of the discovery 578 
and combined meta-analyses are reported with a red and an orange diamond, respectively. The 579 
H3K27Ac mark track (Layered H3K27Ac) shows the levels of enrichment of the H3K27Ac histone 580 
mark. Chemical modifications (e.g. methylation and acylation) to the histone proteins present in 581 
chromatin influence gene expression by changing how accessible the chromatin is to transcription. 582 
The H3K27Ac histone mark is thought to enhance transcription possibly by blocking the spread of the 583 
repressive histone mark H3K27Me3. The GeneHancer (GH) track set shows human regulatory 584 
elements, i.e. enhancers (gray) and promoters (red), containing tracks representing regulatory 585 
elements (Reg Elems), gene transcription start sites (TSS), associations between regulatory elements 586 
and genes (Interactions), and clustered interactions (Clusters). A gray box in the DNaseI 587 
Hypersensitivity Clusters track (DNase Clusters) indicates the extent of the hypersensitive region with 588 
darkness proportional to the maximum signal strength observed in any cell line. A gray box in the 589 
Transcription Factor ChIP-seq Clusters track (Txn Factor ChIP) indicates a cluster of transcription 590 
factor occupancy, with the darkness of the box being proportional to the maximum signal strength 591 
observed in any cell line contributing to the cluster. 592 
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Figure 3. Co-localization results 593 
Illustration of the SMR test for the early repolarization pattern (ERP) risk and the expression 594 
quantitative trait loci (eQTLs) at the rs1545300 locus at chromosome 1p13.2 for (A) left ventricle of the 595 
heart, (B) tibial artery, and (C) minor salivary gland tissue. The sample size for the eQTLs are n=272, 596 
n=388 and n=85 in panels (A), (B) and (C), respectively. In each panel, the upper box shows the 597 
GWAS regional association plot with ERP risk of the combined GWAS (n=39,456), with level of 598 
significance of the SMR test (y-axis) for each transcript in the locus indicated by a diamond positioned 599 
at the center of the transcript. A significant SMR test represented by a purple diamond indicates an 600 
association of the transcript level of the respective genes (purple label) with the trait. For all three 601 
tissues, an increased gene expression level of a significant SMR test was associated with a higher risk 602 
of ERP. A filled purple diamond indicates a HEIDI test p-value >0.05, thus a likely co-localization. The 603 
lower box shows the regional association distribution with changes in expression of the highlighted 604 
(purple) gene transcript in the respective tissue. In both boxes, the x-axis refers to GRCh37/hg19 605 
genomic coordinates. 606 
  607 
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Table 1: Baseline characteristics of the study populations 608 
Study Subgroup 
Number of 
samples 
(n) 
Number of 
females 
(n) 
Age 
in years 
(mean±SD) 
Heart rate 
in bpm 
(mean±SD) 
BMI 
(mean±SD) 
Discovery stage 
 
     BRIGHT ERP+ 189 105 57.6±12.1 61.79.9 27.7±3.4 
 
ERP- 1173 747 59.4±12.3 63.711.2 27.4±3.8 
GHS1 ERP+ 182 60 54.5±10.0 67.6±11.5 26.8±4.4 
 
ERP- 2628 1358 55.6±10.9 69.1±10.8 27.1±4.7 
GHS2 ERP+ 70 26 54.0±10.2 67.1±11.4 27.5±5.5 
 
ERP- 1028 536 54.9±10.9 68.7±10.8 27.2±4.9 
GRAPHIC ERP+ 57 18 52.3±3.9 63.5±8.0 27.4±4.0 
 
ERP- 893 457 52.8±4.5 64.1±9.8 27.4±4.3 
Lifelines ERP+ 1253 639 48.0±11.5 66.3±10.9 25.7±3.8 
 
ERP- 11463 6902 47.9±11.3 68.4±11.5 26.4±4.3 
SHIP ERP+ 173 79 46.6±16.1 70.5±11.6 25.9±4.2 
 
ERP- 2835 1508 48.5±15.8 73.7±11.6 27.3±4.9 
SHIP-Trend ERP+ 86 38 49.8±14.5 64.4±8.9 26.9±4.4 
 
ERP- 848 494 49.7±13.4 65.9±9.6 27.3±4.6 
TwinsUK ERP+ 171 150 51.7±13.2 64.1±10.3 25.3±4.4 
 
ERP- 2773 2651 52.7±12.4 66.8±10.4 25.7±4.6 
Replication stage 
      
CHRIS ERP+ 427 159 45.2±16.3 60.3±8.9 25.4±4.2 
 
ERP- 3953 2318 45.7±16.1 62.5±8.8 25.6±4.6 
Rotterdam Study I ERP+ 308 182 66.4±7.6 68.7±11.6 27.5±7.4 
 
ERP- 4438 2739 66.3±7.7 69.2±11.9 27.1±6.9 
Rotterdam Study II ERP+ 164 84 64.1±7.3 67.5±10.6 27.5±4.1 
 
ERP- 1476 825 64.4±7.5 68.8±10.8 27.5±4.1 
Rotterdam Study III ERP+ 225 116 56.7±5.6 69.0±11.7 27.6±4.9 
 
ERP- 2643 1541 57.0±6.7 69.6±10.5 27.5±5.0 
 609 
ERP+: cases with early repolarization pattern; ERP-: controls 610 
Table 2: Lead SNPs of the GWAS association results 611 
SNP Chr:position 
A1/ 
A2 
Nearest 
gene AF1 
Discovery 
OR P I² N 
Replication 
OR P I² N 
Combined 
OR P I² N 
rs12090194 1:112,454,822 t/c KCND3 0.32 0.80 
[0.75-0.86] 
4.6E-10 34 25177 0.86 
[0.79-0.95] 
2.5E-03 39 13634 0.82 
[0.78-0.87] 
9.3E-12 35 38811 
rs1545300 1:112,464,004 t/c KCND3 0.32 0.81 
[0.75-0.86] 
1.4E-09 41 25172 0.85 
[0.77-0.94] 
9.4E-04 56 13634 0.82 
[0.78-0.87] 
7.7E-12 43 38806 
rs139772527 16:208,761 t/c HBZ 0.01 2.57 
[1.85-3.58] 
2.0E-08 0 21495 1.21 
[0.85-1.73] 
2.8E-01 0 13634 1.81 
[1.42-2.31] 
1.4E-06 11 35129 
 612 
A1: effect allele; AF1: allele frequency of A1; Chr: chromosome; position: position corresponding to 613 
build 37 (GRCh37); OR: odds ratio of A1 [95% confidence interval]; P: association p-value; I²: 614 
percentage of total variation across studies that is due to heterogeneity; N: sample size. Bold values 615 
indicate the lead SNP (lowest p-value) of a significantly associated locus in the corresponding meta-616 
analysis stage. 617 
  618 
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Table 3: The 43 genome-wide significant SNPs of the KCND3 locus 619 
SNP position location A1/A2 AF1 OR P 
rs817972 112,399,057 intron a/g 0.90 1.35 [1.22-1.50] 2.0E-08 
rs583731 112,421,854 intron t/c 0.09 0.69 [0.62-0.77] 3.6E-11 
rs528779 112,424,077 intron t/c 0.71 1.18 [1.11-1.25] 2.0E-08 
rs612790 112,426,577 intron c/g 0.29 0.84 [0.80-0.89] 1.1E-08 
rs2813862 112,427,918 intron c/g 0.29 0.84 [0.79-0.89] 5.9E-09 
rs1767283 112,428,953 intron t/c 0.29 0.84 [0.80-0.89] 8.5E-09 
rs11102354 112,433,666 intron a/g 0.31 1.18 [1.11-1.25] 3.3E-08 
rs605604 112,433,863 intron a/c 0.70 1.19 [1.12-1.26] 6.4E-09 
rs2798334 112,437,344 intron t/c 0.30 0.84 [0.79-0.89] 7.7E-09 
rs2813864 112,437,853 intron a/g 0.29 0.84 [0.79-0.89] 8.2E-09 
rs2587368 112,437,907 intron t/c 0.40 0.86 [0.81-0.90] 1.7E-08 
rs2813865 112,437,956 intron a/g 0.25 0.82 [0.77-0.87] 8.6E-10 
rs894849 112,437,964 intron t/c 0.41 0.86 [0.81-0.90] 1.3E-08 
rs608673 112,439,757 intron t/c 0.44 0.86 [0.81-0.91] 2.0E-08 
rs7539683 112,439,770 intron t/g 0.27 1.20 [1.13-1.27] 2.0E-09 
rs1805222 112,440,983 intron a/g 0.27 1.20 [1.13-1.27] 3.3E-09 
rs2120436 112,451,447 intron t/c 0.32 0.82 [0.78-0.87] 1.7E-11 
rs2034124 112,451,681 intron a/g 0.45 1.16 [1.10-1.22] 1.6E-08 
rs12090194 112,454,822 intron t/c 0.32 0.82 [0.78-0.87] 9.3E-12 
rs72692596 112,455,415 intron t/c 0.32 0.84 [0.79-0.89] 2.8E-09 
rs72692597 112,455,442 intron t/g 0.32 0.84 [0.79-0.89] 2.9E-09 
rs4839182 112,456,538 intron a/g 0.55 1.18 [1.12-1.25] 3.9E-09 
rs4839183 112,456,882 intron a/g 0.46 1.17 [1.11-1.23] 5.3E-09 
rs72692602 112,458,833 intron t/c 0.68 1.20 [1.13-1.27] 2.5E-09 
rs72694603 112,458,893 intron t/c 0.32 0.83 [0.79-0.89] 2.3E-09 
rs4839184 112,460,221 intron c/g 0.32 0.83 [0.78-0.87] 2.6E-11 
rs4839185 112,460,262 intron t/c 0.68 1.21 [1.15-1.28] 1.4E-11 
rs1443926 112,461,902 intron a/g 0.68 1.21 [1.15-1.28] 2.0E-11 
rs6682872 112,462,984 intron a/g 0.60 1.18 [1.12-1.24] 9.6E-10 
rs4838926 112,463,323 intron c/g 0.40 0.85 [0.81-0.90] 2.0E-09 
rs4838927 112,463,617 intron t/c 0.60 1.18 [1.12-1.24] 1.7E-09 
rs1545300 112,464,004 intron t/c 0.32 0.82 [0.78-0.87] 7.7E-12 
rs17029069 112,464,376 intron t/c 0.30 1.21 [1.14-1.28] 1.1E-10 
rs12119724 112,468,814 intron t/c 0.29 1.21 [1.14-1.28] 7.3E-11 
rs11588747 112,470,474 intron t/c 0.70 1.19 [1.12-1.27] 1.5E-08 
rs2010749 112,470,581 intron t/c 0.63 1.20 [1.14-1.27] 3.7E-11 
rs1443927 112,471,029 intron c/g 0.69 1.20 [1.14-1.28] 1.9E-10 
rs12145374 112,480,536 intron a/c 0.80 1.22 [1.14-1.30] 8.6E-09 
rs72694622 112,481,667 intron t/c 0.18 0.81 [0.75-0.87] 3.6E-08 
rs12144965 112,484,962 intron t/c 0.82 1.23 [1.14-1.32] 2.8E-08 
rs3008527 112,523,095 intron t/c 0.70 1.19 [1.12-1.26] 5.8E-09 
rs3008528 112,527,869 intron a/t 0.70 1.18 [1.11-1.25] 1.7E-08 
rs2075811 112,530,626 intron c/g 0.30 0.85 [0.80-0.90] 1.7E-08 
 620 
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A1: effect allele; AF1: allele frequency of A1; position on chromosome 1 (build 37, GRCh37); OR: 621 
odds ratio of A1 [95% confidence interval]; P: association p-value. The SNPs are ordered by their 622 
position, and the results of the combined meta-analysis are given. 623 



